Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 2/20 | 1.00 |
| ▸ | PDPK1 | O15530 | 3/20 | 0.56 |
| ▸ | GAA | P10253 | 2/20 | 0.56 |
| ▸ | KDR | P35968 | 6/20 | 0.50 |
| ▸ | KIT | P10721 | 2/20 | 0.50 |
| ▸ | FLT3 | P36888 | 2/20 | 0.50 |
| ▸ | ABL1 | P00519 | 5/20 | 0.47 |
| ▸ | ROCK1 | Q13464 | 4/20 | 0.47 |
| ▸ | CDK5 | Q00535 | 4/20 | 0.47 |
| ▸ | LCK | P06239 | 3/20 | 0.47 |
| ▸ | CSF1R | P07333 | 3/20 | 0.47 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.47 |
| ▸ | PRKACA | P17612 | 3/20 | 0.47 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.47 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.47 |
| ▸ | PLK4 | O00444 | 2/20 | 0.47 |
| ▸ | AURKA | O14965 | 2/20 | 0.47 |
| ▸ | JAK2 | O60674 | 2/20 | 0.47 |
| ▸ | CDK1 | P06493 | 2/20 | 0.47 |
| ▸ | LYN | P07948 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22499298 | 0.82 | MAP2K1 (0.70) | MAP2K1PDPK1GAAKDRKIT | |
| SCHEMBL27697246 | 0.79 | MAP2K1 (0.65) | MAP2K1PDPK1GAAKDRFLT3 | |
| SCHEMBL14631605 | 0.79 | MAP2K1 (0.65) | MAP2K1PDPK1GAAKDRKIT | |
| SCHEMBL30548021 | 0.79 | MAP2K1 (0.65) | MAP2K1PDPK1GAAKDRKIT | |
| SCHEMBL25249427 | 0.79 | MAP2K1 (0.65) | MAP2K1PDPK1GAAKDRKIT | |
| SCHEMBL17424248 | 0.77 | KDR (0.66) | MAP2K1PDPK1GAAKDRKIT | |
| SCHEMBL30065304 | 0.75 | PDPK1 (0.66) | MAP2K1PDPK1GAAKDRKIT | |
| SCHEMBL628649 | 0.75 | PDPK1 (0.66) | MAP2K1PDPK1GAAKDRKIT | |
| SCHEMBL29950691 | 0.75 | MAP2K1 (0.59) | MAP2K1PDPK1GAAKDRKIT | |
| SCHEMBL16681490 | 0.75 | MAP2K1 (0.59) | MAP2K1PDPK1GAAKDRKIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10668071-B2 | (Aza)pyridopyrazolopyrimidinones and indazolopyrimidinones and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2020-06-02 | — | — | US | disclosed |
| US-10668071-B2 | (Aza)pyridopyrazolopyrimidinones and indazolopyrimidinones and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2020-06-02 | — | — | US | disclosed |
| EP-3066100-B1 | (AZA)PYRIDOPYRAZOLOPYRIMIDINONES AND INDAZOLOPYRIMIDINONES AS INHIBITORS OF FIBRINOLYSIS | Bayer Pharma AG (DE) | 2019-04-17 | — | — | EP | disclosed |
| EP-3066100-B1 | (AZA)PYRIDOPYRAZOLOPYRIMIDINONES AND INDAZOLOPYRIMIDINONES AS INHIBITORS OF FIBRINOLYSIS | Bayer Pharma AG (DE) | 2019-04-17 | — | — | EP | disclosed |
| US-20180344739-A1 | (AZA)PYRIDOPYRAZOLOPYRIMIDINONES AND INDAZOLOPYRIMIDINONES AND THEIR USE | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-12-06 | — | — | US | disclosed |
| US-10098883-B2 | (Aza)pyridopyrazolopyrimidinones and indazolopyrimidinones and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-10-16 | — | — | US | disclosed |
| US-20170239251-A1 | (AZA)PYRIDOPYRAZOLOPYRIMIDINONES AND INDAZOLOPYRIMIDINONES AND THEIR USE | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-08-24 | — | — | US | disclosed |
| US-20170239251-A1 | (AZA)PYRIDOPYRAZOLOPYRIMIDINONES AND INDAZOLOPYRIMIDINONES AND THEIR USE | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-08-24 | — | — | US | disclosed |
| US-20170239251-A1 | (AZA)PYRIDOPYRAZOLOPYRIMIDINONES AND INDAZOLOPYRIMIDINONES AND THEIR USE | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-08-24 | — | — | US | disclosed |
| US-9598417-B2 | (Aza)pyridopyrazolopyrimidinones and indazolopyrimidinones and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-03-21 | — | — | US | disclosed |
| CN-102388039-A | Pyrazole derivatives as CCR4 receptor antagonists | GLAXO GROUP LTD | 2012-03-21 | — | — | CN | disclosed |
| US-20120015932-A1 | Pyrazole Derivatives Used as CCR4 Receptor Antagonists | GLAXO GROUP LIMITED (GB) | 2012-01-19 | — | — | US | disclosed |
| US-20120015932-A1 | Pyrazole Derivatives Used as CCR4 Receptor Antagonists | GLAXO GROUP LIMITED (GB) | 2012-01-19 | — | — | US | disclosed |
| US-20120015932-A1 | Pyrazole Derivatives Used as CCR4 Receptor Antagonists | GLAXO GROUP LIMITED (GB) | 2012-01-19 | — | — | US | disclosed |
| EP-2401270-A1 | PYRAZOLE DERIVATIVES USED AS CCR4 RECEPTOR ANTAGONISTS | Glaxo Group Limited (GB) | 2012-01-04 | — | — | EP | disclosed |
| WO-2010097395-A1 | PYRAZOLE DERIVATIVES USED AS CCR4 RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2010-09-02 | — | — | WO | disclosed |
| WO-2010097395-A1 | PYRAZOLE DERIVATIVES USED AS CCR4 RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2010-09-02 | — | — | WO | disclosed |
| US-20100216860-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-08-26 | — | — | US | disclosed |
| US-20100216860-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-08-26 | — | — | US | disclosed |
| US-20100216860-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180344739-A1 | (AZA)PYRIDOPYRAZOLOPYRIMIDINONES AND INDAZOLOPYRIMIDINONES AND THEIR USE | SERPINB6, SERPINC1, SERPINE1 | MAP2K1 1165/4885PDPK1 1304/4885GAA 3619/4885 |
| US-10668071-B2 | (Aza)pyridopyrazolopyrimidinones and indazolopyrimidinones and their use | SERPINB6, SERPINC1, SERPINE1 | MAP2K1 1165/4885PDPK1 1304/4885GAA 3619/4885 |
| US-20120015932-A1 | Pyrazole Derivatives Used as CCR4 Receptor Antagonists | CCR4, CCR3, CCR1 | MAP2K1 3016/4885PDPK1 610/4885GAA 4288/4885 |
| US-20170239251-A1 | (AZA)PYRIDOPYRAZOLOPYRIMIDINONES AND INDAZOLOPYRIMIDINONES AND THEIR USE | SERPINB6, SERPINC1, SERPINE1 | MAP2K1 1165/4885PDPK1 1304/4885GAA 3619/4885 |
| US-10098883-B2 | (Aza)pyridopyrazolopyrimidinones and indazolopyrimidinones and their use | SERPINB6, SERPINC1, SERPINE1 | MAP2K1 1165/4885PDPK1 1304/4885GAA 3619/4885 |
| US-20100216860-A1 | NOVEL COMPOUNDS | CYP3A4, CYP3A43, ABCG2 | MAP2K1 4755/4885PDPK1 221/4885GAA 303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.